Curated News
By: NewsRamp Editorial Staff
June 11, 2026
Helix BioPharma Reports Improved Financials, Advances Pipeline
TLDR
- Helix BioPharma raised $3.7M and targets a US exchange listing, potentially increasing liquidity and investor access.
- Helix reduced net loss to $671K for Q3 2026 by closing LDOS006 study and cutting R&D expenses, while securing convertible debt.
- Helix advances L-DOS47 and oral cancer treatments to make hard-to-treat cancers vincible, improving patient outcomes.
- Helix's GEMCEDA is a first-in-class oral gemcitabine prodrug with bioavailability matching IV administration.
Impact - Why it Matters
This news matters because Helix BioPharma is making tangible progress in its mission to tackle hard-to-treat cancers, with a strengthened financial position and a clear strategy for growth. The improved cash position and reduced losses suggest the company is managing its resources effectively, while the planned U.S. exchange listing could open doors to greater investment and accelerate development of promising therapies like L-DOS47. For investors and patients, this signals that Helix is moving closer to bringing novel treatments to market, potentially offering new hope for cancers that are currently difficult to treat.
Summary
Helix BioPharma Corp., a clinical-stage oncology company, has announced its financial results for the three and nine months ended April 30, 2026, highlighting a strategic focus on securing capital and advancing its pipeline. The company, led by CEO Thomas Mehrling, MD, PhD, reported a net loss of $671,000 for the quarter, a significant improvement from $1.544 million in the same period last year, driven by reduced R&D expenses and the winding down of its LDOS006 clinical study. Cash reserves surged to $2.842 million from $65,000 as of July 31, 2025, bolstered by a private placement of convertible debentures that raised $3.673 million in proceeds. The company is also pursuing a U.S. exchange listing to expand access to capital and is working with legal advisors on a base shelf prospectus.
Helix’s pipeline is led by L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing tumors, which has completed Phase Ib studies in non-small cell lung cancer. The company is also advancing pre-IND candidates LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. These developments are part of Helix’s mission to make hard-to-treat cancers vincible. The full details are available in the Interim Filings on www.sedarplus.ca and the company’s website.
Financially, Helix is focusing on extending its operating runway to approximately twelve months, with the recent private placement being a key milestone. The company is also evaluating financing alternatives, including potential partnerships and a U.S. exchange listing, to support ongoing operations and long-term shareholder value. The financial results reflect a disciplined approach to cash management, with reduced losses and increased cash reserves, positioning Helix for its next phase of growth as it advances its oncology pipeline toward the clinic.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Helix BioPharma Reports Improved Financials, Advances Pipeline
